UK launch for Mylan, Biocon insulin glargine biosimilar Semglee
Mylan and Biocon have announced the UK launch of Semglee – an approved biosimilar of reference medicine insulin glargine.
Read More
Tag: Biocon
US OKs first biosimilar of Amgen’s Neulasta
Mylan and Biocon’s Fulphila has become the first biosimilar of Amgen’s Neulasta to be approved by the US Food and Drug Administration.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
